Verastem (VSTM) Total Non-Current Liabilities (2012 - 2026)
Verastem (VSTM) posted quarterly Total Non-Current Liabilities of $146.0 million for Q1 2026, up 33.5% year-over-year from $109.4 million in Q1 2025, and down 4.93% quarter-over-quarter from $153.6 million in Q4 2025.
Analysis
Verastem (VSTM) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Verastem's Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $146.0 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 33.5% year-over-year to $146.0 million; the TTM figure through Mar 2026 stood at $146.0 million (up 33.5% YoY), while the FY2025 annual figure was $153.6 million, up 112.65% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $146.0 million, down from $153.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $153.6 million in Q4 2025, with the low at $68.0 million in Q3 2024.
- The 4-year median for Total Non-Current Liabilities is $126.7 million (2025), against an average of $114.7 million.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities declined 5.21% in 2024, then surged 112.65% in 2025.
- Verastem's Total Non-Current Liabilities stood at $71.8 million in 2023, then gained by 0.65% to $72.2 million in 2024, then soared by 112.65% to $153.6 million in 2025, then fell by 4.93% to $146.0 million in 2026.
- Business Quant data shows VSTM's Total Non-Current Liabilities at $146.0 million in Q1 2026, $153.6 million in Q4 2025, and $144.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | 156.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 156.53 Mn |
| Mar 31, 2026 | 146.03 Mn |
| Dec 31, 2025 | 153.60 Mn |
| Sep 30, 2025 | 144.09 Mn |
| Jun 30, 2025 | 138.45 Mn |
| Mar 31, 2025 | 109.39 Mn |
| Dec 31, 2024 | 72.23 Mn |
| Sep 30, 2024 | 68.02 Mn |
| Sep 30, 2023 | 71.76 Mn |
| Jun 30, 2020 | 83.29 Mn |
| Mar 31, 2020 | 84.30 Mn |
| Dec 31, 2019 | 137.00 Mn |
| Sep 30, 2019 | 170.21 Mn |
| Jun 30, 2019 | 168.73 Mn |
| Mar 31, 2019 | 154.41 Mn |
| Dec 31, 2018 | 151.81 Mn |
| Sep 30, 2018 | 74.98 Mn |
| Jun 30, 2018 | 45.65 Mn |
| Mar 31, 2018 | 29.76 Mn |
| Dec 31, 2017 | 31.96 Mn |